scholarly journals What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?

2015 ◽  
Vol 6 (5) ◽  
pp. 117-119 ◽  
Author(s):  
Zobair Younossi
Keyword(s):  
Hepatitis C ◽  
Antiviral Agents ◽  
Ethical Responsibility ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Eric G. Meissner ◽  
Amy Nelson ◽  
Miriam Marti ◽  
Henry Masur ◽  
Anu Osinusi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Antiviral Agents ◽  
Virologic Response ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Abstract Successful treatment of chronic hepatitis C virus infection can now be achieved using direct-acting antiviral agents without interferon. In this report, we present a patient who achieved a sustained virologic response after 27 days of treatment with sofosbuvir and ribavirin. It is imperative to identify factors that allow for shorter treatment times in some individuals.

scholarly journals Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Abdulrahman Qatomah ◽  
Majidah Bukhari ◽  
Edward Cupler ◽  
Hosam Alardati ◽  
Mohammad Mawardi
Keyword(s):  
Creatine Kinase ◽  
Hepatitis C ◽  
Dehydrogenase Deficiency ◽  
Antiviral Agents ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Chain Acyl ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents ◽  
Long Chain

Abstract Introduction Treatment of hepatitis C infection has evolved dramatically since 2011. Previous conventional therapy with interferon and ribavirin used to have a low sustained virological response rate of less than 40%. In the new direct-acting antiviral therapy era, a sustained virological response can be achieved in more than 90% of cases. Case presentation We report a rare case of severe reversible acute rhabdomyolysis in a 31-year-old Saudi male patient with very long-chain acyl-coenzyme A dehydrogenase deficiency and chronic hepatitis C infection. The patient was clinically asymptomatic with no signs of decompensated liver disease. The patient received new direct-acting antiviral agents: sofosbuvir and daclatasvir. Fourteen days after initiation of direct-acting antiviral agents, the patient was found to have asymptomatic rhabdomyolysis. His creatine kinase peaked at 2572 IU/l, and he was treated conservatively; the direct-acting antiviral agents were discontinued and within 7 days, the patient’s creatine kinase levels normalized. Conclusion This case highlights possible direct-acting antiviral agent-induced rhabdomyolysis in a patient with very-long-chain acyl-CoA dehydrogenase deficiency, presumably through alteration of mitochondrial membrane potential. Further studies are required to assess the possible impact and associations.

Sign in / Sign up

Export Citation Format

Share Document